Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how? [0.03%]
异基因造血细胞移植治疗MDS：适合哪种患者、何时及如何进行？
Boglarka Gyurkocza,H Joachim Deeg
Boglarka Gyurkocza
Hematopoietic cell transplantation (HCT) is currently the only treatment with curative potential for patients with myelodysplastic syndrome (MDS). However, treatment-related mortality and relapse have remained major barriers to uniform succ...
Improving outcomes in umbilical cord blood transplantation: state of the art [0.03%]
改善脐带血移植预后的研究新进展——现状及展望
Corey Cutler,Karen K Ballen
Corey Cutler
Only 30% of patients who require an allogeneic hematopoietic cell transplant will have a HLA matched sibling donor. Many patients, particularly those patients with diverse racial and ethnic backgrounds, may not be able to identify a suitabl...
Andrew S Epstein,Gabrielle R Goldberg,Diane E Meier
Andrew S Epstein
Palliative medicine provides active evaluation and treatment of the physical, psychosocial and spiritual needs of patients and families with serious illnesses, regardless of curability or stage of illness. The hematologic malignancies compr...
Nicola S Curry,Ross A Davenport,Beverley J Hunt et al.
Nicola S Curry et al.
Uncontrolled bleeding is the most common preventable cause of death for patients with severe injury. Coagulopathy inevitably accompanies severe bleeding, exacerbated by the ongoing blood loss and the treatments administered. There is debate...
Front-line therapy in polycythemia vera and essential thrombocythemia [0.03%]
原发性血小板增多症和真性红细胞增多症的一线治疗
Tiziano Barbui,Maria Chiara Finazzi,Guido Finazzi
Tiziano Barbui
Because the current therapy in polycythemia vera (PV) and essential thrombocythemia (ET) is aimed at lowering the risk of thrombosis, the risk classification system in these disorders is shaped according to thrombotic risk. Patients with ei...
David Stephensen,Wendy I Drechsler,Oona M Scott
David Stephensen
Intermittent joint bleeding and potential arthropathy remain a concern for patients and those responsible for haemophilic care. Monitoring the status of haemophilic joints is a current challenge. Evaluation of bone and soft tissue with radi...
Raed Al Dieri,Bas de Laat,H Coenraad Hemker
Raed Al Dieri
Thrombin is a pivotal player in the coagulation system. In clotting blood a transient wave of thrombin appears after a lag time. Clotting occurs at the start of the wave. The amount of thrombin formed reflects the function of the hemostatic...
K P M van Galen,A Tuinenburg,E M Smeets et al.
K P M van Galen et al.
Von Willebrand factor (VWF) is a large multimeric glycoprotein that plays a major role in haemostasis, illustrated by the bleeding tendency in von Willebrand disease (VWD), the most common hereditary bleeding disorder caused by VWF deficien...
Yona Nadir,Benjamin Brenner
Yona Nadir
Thrombotic complications are common in stem cell transplantation (SCT) recipients and endothelial cell injury is a dominant contributing factor to the hemostatic impairments. Endothelial cells line the vascular bed and each vascular bed has...
Recent advances in the molecular understanding of non-transfusion-dependent thalassemia [0.03%]
recent advances in the molecular understanding of non-transfusion-dependent thalassemia（非输血依赖性地中海贫血分子机制的最新研究进展）
Renzo Galanello
Renzo Galanello
Thalassemias are a group of inherited autosomal recessive hematologic disorders that occur because of defects in the alpha (α)- and beta (β)-globin genes of adult hemoglobin (Hb). An imbalance in the synthesis of one or more of the globin...